Sialidosis: Current Treatment Options and Symptom Management Strategies

Disease Overview

Sialidosis (neuraminidase deficiency) is an autosomal recessive lysosomal storage disorder caused by NEU1 mutations. Deficient sialidase leads to accumulation of sialylated oligosaccharides/glycoproteins. Two phenotypes: Type I (milder, adolescent onset, cherry-red spot, myoclonus) and Type II (severe, infantile, dysmorphism, organomegaly, developmental regression).

Current Management (No Cure)

  • Symptomatic care: Anticonvulsants for myoclonus/seizures; physical/occupational therapy for mobility; speech/swallowing therapy.
  • Respiratory support: For recurrent aspiration or restrictive lung disease.
  • Enzyme replacement therapy (ERT): Investigational; recombinant human NEU1 has shown substrate reduction in models; clinical trials ongoing.
  • Substrate reduction therapy: Not yet established.
  • Gene therapy: AAV-NEU1 vectors in preclinical/early clinical stages.
  • Hematopoietic stem cell transplant (HSCT): Limited experience; may stabilize neurocognitive decline in Type II if done early.

Multidisciplinary Care

Genetics, neurology, pulmonology, orthopedics, ophthalmology, palliative care. Genetic counseling for family.

Prognosis

Type I: near-normal lifespan with disability. Type II: life-limiting, often childhood mortality. Research into disease-modifying therapies is active.

Bulimia - Related Articles